Open Label, Multi-Center, Randomized Safety, Feasibility and Tolerability Pilot Study of Pegasys (Peginterferon Alfa-2a) Copegus (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program

Trial Profile

Open Label, Multi-Center, Randomized Safety, Feasibility and Tolerability Pilot Study of Pegasys (Peginterferon Alfa-2a) Copegus (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 04 Feb 2016 Change in treatment table: oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3 added in treatments as per ClinicalTrials.gov record.
    • 02 Jun 2010 New source identified and integrated (Roche)
    • 26 Jun 2007 Status changed from in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top